299 related articles for article (PubMed ID: 32625254)
1. Update: use of the benchmark dose approach in risk assessment.
; Hardy A; Benford D; Halldorsson T; Jeger MJ; Knutsen KH; More S; Mortensen A; Naegeli H; Noteborn H; Ockleford C; Ricci A; Rychen G; Silano V; Solecki R; Turck D; Aerts M; Bodin L; Davis A; Edler L; Gundert-Remy U; Sand S; Slob W; Bottex B; Abrahantes JC; Marques DC; Kass G; Schlatter JR
EFSA J; 2017 Jan; 15(1):e04658. PubMed ID: 32625254
[TBL] [Abstract][Full Text] [Related]
2. Guidance on the use of the benchmark dose approach in risk assessment.
; More SJ; Bampidis V; Benford D; Bragard C; Halldorsson TI; Hernández-Jerez AF; Bennekou SH; Koutsoumanis K; Lambré C; Machera K; Mennes W; Mullins E; Nielsen SS; Schrenk D; Turck D; Younes M; Aerts M; Edler L; Sand S; Wright M; Binaglia M; Bottex B; Abrahantes JC; Schlatter J
EFSA J; 2022 Oct; 20(10):e07584. PubMed ID: 36304832
[TBL] [Abstract][Full Text] [Related]
3. Determination of a site-specific reference dose for methylmercury for fish-eating populations.
Shipp AM; Gentry PR; Lawrence G; Van Landingham C; Covington T; Clewell HJ; Gribben K; Crump K
Toxicol Ind Health; 2000 Nov; 16(9-10):335-438. PubMed ID: 11762928
[TBL] [Abstract][Full Text] [Related]
4. Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data.
Zhu Y; Wang T; Jelsovsky JZ
Risk Anal; 2007 Apr; 27(2):447-65. PubMed ID: 17511711
[TBL] [Abstract][Full Text] [Related]
5. Benchmark dose and the three Rs. Part I. Getting more information from the same number of animals.
Slob W
Crit Rev Toxicol; 2014 Aug; 44(7):557-67. PubMed ID: 25000332
[TBL] [Abstract][Full Text] [Related]
6. Does EU legislation allow the use of the Benchmark Dose (BMD) approach for risk assessment?
Brandon EF; Bulder AS; van Engelen JG; Mahieu CM; Mennes WC; Pronk ME; Rietveld AG; van de Ven BM; Ten Voorde SE; Wolterink G; Slob W; Zeilmaker MJ; Bessems JG
Regul Toxicol Pharmacol; 2013 Nov; 67(2):182-8. PubMed ID: 23871753
[TBL] [Abstract][Full Text] [Related]
7. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
Filipsson AF; Sand S; Nilsson J; Victorin K
Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the lower limit of benchmark dose confidence interval with no-observed-adverse-effect level by applying four different software for tumorigenicity testing of pesticides in Japan.
Yasuhiko Y; Ishigami M; Machino S; Fujii T; Aoki M; Irie F; Kanda Y; Yoshida M
Regul Toxicol Pharmacol; 2022 Aug; 133():105201. PubMed ID: 35691450
[TBL] [Abstract][Full Text] [Related]
9. Application of benchmark dose for occupational epidemiology in lead exposure.
Lin T; Xiao-Ting L; Ai G; Qiu-Ying L; Tai-Yi J
Toxicol Mech Methods; 2008; 18(4):363-7. PubMed ID: 20020903
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the benchmark dose for point of departure determination for a variety of chemical classes in applied regulatory settings.
Izadi H; Grundy JE; Bose R
Risk Anal; 2012 May; 32(5):830-5. PubMed ID: 22126138
[TBL] [Abstract][Full Text] [Related]
11. Model Uncertainty and Bayesian Model Averaged Benchmark Dose Estimation for Continuous Data.
Shao K; Gift JS
Risk Anal; 2014 Jan; 34(1):101-20. PubMed ID: 23758102
[TBL] [Abstract][Full Text] [Related]
12. Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach.
Bokkers BG; Slob W
Crit Rev Toxicol; 2007 Jun; 37(5):355-73. PubMed ID: 17612951
[TBL] [Abstract][Full Text] [Related]
13. Introduction to benchmark dose methods and U.S. EPA's benchmark dose software (BMDS) version 2.1.1.
Davis JA; Gift JS; Zhao QJ
Toxicol Appl Pharmacol; 2011 Jul; 254(2):181-91. PubMed ID: 21034758
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of subchronic toxicity data using the benchmark dose approach.
Gephart LA; Salminen WF; Nicolich MJ; Pelekis M
Regul Toxicol Pharmacol; 2001 Feb; 33(1):37-59. PubMed ID: 11259178
[TBL] [Abstract][Full Text] [Related]
15. The use of benchmark dose uncertainty measurements for robust comparative potency analyses.
Wheeldon RP; Dertinger SD; Bryce SM; Bemis JC; Johnson GE
Environ Mol Mutagen; 2021 Mar; 62(3):203-215. PubMed ID: 33428310
[TBL] [Abstract][Full Text] [Related]
16. Determination of benchmark doses for linear furanocoumarin consumption associated with inhibition of cytochrome P450 1A2 isoenzyme activity in healthy human adults.
Alehaideb Z; Matou-Nasri S
Toxicol Rep; 2021; 8():1437-1444. PubMed ID: 34377680
[TBL] [Abstract][Full Text] [Related]
17. Variation in benchmark dose (BMD) and the 95% lower confidence limit of benchmark dose (BMDL) among general Japanese populations with no anthropogenic exposure to cadmium.
Sakuragi S; Takahashi K; Hoshuyama T; Moriguchi J; Ohashi F; Fukui Y; Ikeda M
Int Arch Occup Environ Health; 2012 Nov; 85(8):941-50. PubMed ID: 22270387
[TBL] [Abstract][Full Text] [Related]
18. Benchmark dose modelling in regulatory ecotoxicology, a potential tool in pest management.
Jensen SM; Kluxen FM; Ritz C
Pest Manag Sci; 2022 May; 78(5):1772-1779. PubMed ID: 34908226
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. A Web-Based System for Bayesian Benchmark Dose Estimation.
Shao K; Shapiro AJ
Environ Health Perspect; 2018 Jan; 126(1):017002. PubMed ID: 29329100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
